Overview

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
SkyePharma AG
Collaborator:
Abbott
Treatments:
Fluticasone
Formoterol Fumarate
Xhance